Header Logo

Connection

Jonathan Kay to Humans

This is a "connection" page, showing publications Jonathan Kay has written about Humans.
Connection Strength

1.505
  1. Kay J, Nikolov NP, Weisman MH. American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17-18, 2022. Arthritis Rheumatol. 2024 Sep; 76(9):1323-1333.
    View in: PubMed
    Score: 0.036
  2. Kay J, Cross RK, Feldman SR, Park Y, Hanauer SB. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 02; 41(2):509-533.
    View in: PubMed
    Score: 0.034
  3. Reginato AM, Petri MA, Kay J. Walter Bauer, Marian Wilkins Ropes, and the Massachusetts General Hospital. Rheum Dis Clin North Am. 2024 02; 50(1):79-92.
    View in: PubMed
    Score: 0.034
  4. Kay J, Bock AE, Rehman M, Zhang W, Zhang M, Iikuni N, Alvarez DF. Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis. RMD Open. 2022 09; 8(2).
    View in: PubMed
    Score: 0.032
  5. Yu KS, Jang IJ, Lim HS, Hong JH, Kim MG, Park MK, Cho DY, Park MS, Chung JY, Ghim JL, Lee S, Yoon SK, Kwon IS, Lee SJ, Kim SH, Bae YJ, Cha JB, Furst DE, Keystone E, Kay J. Pharmacokinetic equivalence of CT-P17 to high-concentration (100?mg/ml) reference adalimumab: A randomized phase I study in healthy subjects. Clin Transl Sci. 2021 07; 14(4):1280-1291.
    View in: PubMed
    Score: 0.028
  6. Kay J, Jaworski J, Wojciechowski R, Wiland P, Dudek A, Krogulec M, Jeka S, Zielinska A, Trefler J, Bartnicka-Maslowska K, Krajewska-Wlodarczyk M, Klimiuk PA, Lee SJ, Bae YJ, Yang GE, Yoo JK, Furst DE, Keystone E. Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Res Ther. 2021 02 05; 23(1):51.
    View in: PubMed
    Score: 0.028
  7. Alvarez DF, Wolbink G, Cronenberger C, Orazem J, Kay J. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States? BioDrugs. 2020 Dec; 34(6):723-732.
    View in: PubMed
    Score: 0.028
  8. Liu SH, Shridharmurthy D, Lapane KL, Dub? CE, Gravallese EM, Kay J. Physical Activity and Attitudes Toward Exercise in People With Axial and Peripheral Spondyloarthritis. J Rheumatol. 2021 04; 48(4):513-519.
    View in: PubMed
    Score: 0.028
  9. Kay J, Harigai M, Rancourt J, Dickson C, Melby T, Issa M, de la Torre I, Isaka Y, Cardoso A, Saifan C, Keystone EC, van Vollenhoven RF, Giles JT, Huizinga TW, Kremer JM. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 2020 10; 6(3).
    View in: PubMed
    Score: 0.028
  10. Baker JF, Leonard CE, Lo Re V, Weisman MH, George MD, Kay J. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis Rheumatol. 2020 07; 72(7):1067-1071.
    View in: PubMed
    Score: 0.027
  11. Kay J. Overcoming barriers to biosimilars in inflammatory arthritis. Nat Rev Rheumatol. 2020 Feb; 16(2):65-66.
    View in: PubMed
    Score: 0.026
  12. Liu SH, Morais SA, Lapane KL, Kay J. Physical activity and attitudes and perceptions towards physical activity in patients with spondyloarthritis: A systematic review. Semin Arthritis Rheum. 2020 04; 50(2):289-302.
    View in: PubMed
    Score: 0.026
  13. Salomon-Escoto K, Kay J. The "Treat to Target" Approach to Rheumatoid Arthritis. Rheum Dis Clin North Am. 2019 11; 45(4):487-504.
    View in: PubMed
    Score: 0.025
  14. Kay J, Schwartzman S. Controversies in Rheumatology. Rheum Dis Clin North Am. 2019 08; 45(3):xv-xvi.
    View in: PubMed
    Score: 0.025
  15. Kay J. Are There Benefits and Risks to Biosimilars from a Patient Perspective? Rheum Dis Clin North Am. 2019 08; 45(3):465-476.
    View in: PubMed
    Score: 0.025
  16. Kay J. A 'wind of change' to biosimilars: The NOR-SWITCH trial and its extension. J Intern Med. 2019 06; 285(6):693-695.
    View in: PubMed
    Score: 0.025
  17. Kay J, Schoels MM, D?rner T, Emery P, Kvien TK, Smolen JS, Breedveld FC. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018 02; 77(2):165-174.
    View in: PubMed
    Score: 0.022
  18. Cohen S, Kay J. Biosimilars: implications for rheumatoid arthritis therapy. Curr Opin Rheumatol. 2017 05; 29(3):260-268.
    View in: PubMed
    Score: 0.022
  19. Braun J, Kay J. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2017 Mar; 16(3):289-302.
    View in: PubMed
    Score: 0.021
  20. Schaub S, Sirkis HM, Kay J. Imaging for Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome. Rheum Dis Clin North Am. 2016 11; 42(4):695-710.
    View in: PubMed
    Score: 0.021
  21. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Zhou Y, Goldstein N, Braun J. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Rheumatol. 2016 12; 43(12):2120-2130.
    View in: PubMed
    Score: 0.021
  22. Lambert J, Wyand M, Lassen C, Shneyer L, Thomson E, Knight A, Willers J, Kay J. Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. Int J Clin Pharmacol Ther. 2016 Apr; 54(4):315-22.
    View in: PubMed
    Score: 0.020
  23. Todd DJ, Kay J. Gadolinium-Induced Fibrosis. Annu Rev Med. 2016; 67:273-91.
    View in: PubMed
    Score: 0.020
  24. D?rner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015 Dec; 11(12):713-24.
    View in: PubMed
    Score: 0.019
  25. Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Wolf M, Kay J. Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. Rheumatology (Oxford). 2014 Sep; 53(9):1613-7.
    View in: PubMed
    Score: 0.018
  26. Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg JD, Reed GW, Gravallese EM, Furst DE. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther. 2014 Feb 03; 16(1):R40.
    View in: PubMed
    Score: 0.017
  27. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015 Mar; 74(3):538-46.
    View in: PubMed
    Score: 0.017
  28. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, Casado G, Detert J, El-Zorkany B, Emery P, Hajjaj-Hassouni N, Harigai M, Luo SF, Kurucz R, Maciel G, Mola EM, Montecucco CM, McInnes I, Radner H, Smolen JS, Song YW, Vonkeman HE, Winthrop K, Kay J. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014 Jan; 73(1):62-8.
    View in: PubMed
    Score: 0.017
  29. Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis. 2013 Oct; 72(10):1589-93.
    View in: PubMed
    Score: 0.017
  30. Chopra R, Chaudhary N, Kay J. Relapsing polychondritis. Rheum Dis Clin North Am. 2013 May; 39(2):263-76.
    View in: PubMed
    Score: 0.016
  31. Kay J. Rheumatic rarities. Preface. Rheum Dis Clin North Am. 2013 May; 39(2):xv-xvi.
    View in: PubMed
    Score: 0.016
  32. Kay J, Gravallese EM. Rheumatoid arthritis: erosion defined: back to basics. Nat Rev Rheumatol. 2013 Jun; 9(6):323-4.
    View in: PubMed
    Score: 0.016
  33. Lima XT, Alora-Palli MB, Kimball AB, Kay J. Validation of a screening instrument for nephrogenic systemic fibrosis. Arthritis Care Res (Hoboken). 2013 Apr; 65(4):637-42.
    View in: PubMed
    Score: 0.016
  34. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford). 2012 Dec; 51 Suppl 6:vi28-36.
    View in: PubMed
    Score: 0.016
  35. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012 Dec; 51 Suppl 6:vi5-9.
    View in: PubMed
    Score: 0.016
  36. Bernstein EJ, Schmidt-Lauber C, Kay J. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol. 2012 Aug; 26(4):489-503.
    View in: PubMed
    Score: 0.016
  37. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology--"O brave new world". Nat Rev Rheumatol. 2012 06 05; 8(7):430-6.
    View in: PubMed
    Score: 0.015
  38. Salomon-Escoto KI, Gravallese EM, Kay J. Assessment of control of rheumatoid arthritis disease activity. Best Pract Res Clin Rheumatol. 2011 Aug; 25(4):497-507.
    View in: PubMed
    Score: 0.015
  39. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther. 2011 May 12; 13(3):112.
    View in: PubMed
    Score: 0.014
  40. Kay J, Czirj?k L. Gadolinium and systemic fibrosis: guilt by association. Ann Rheum Dis. 2010 Nov; 69(11):1895-7.
    View in: PubMed
    Score: 0.014
  41. Lebiedz-Odrobina D, Kay J. Rheumatic manifestations of diabetes mellitus. Rheum Dis Clin North Am. 2010 Nov; 36(4):681-99.
    View in: PubMed
    Score: 0.014
  42. Abujudeh HH, Rolls H, Kaewlai R, Agarwal S, Gebreananya ZA, Saini S, Schaefer PW, Kay J. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging. 2009 Dec; 30(6):1335-40.
    View in: PubMed
    Score: 0.013
  43. Koreishi AF, Nazarian RM, Saenz AJ, Klepeis VE, McDonald AG, Farris AB, Colvin RB, Duncan LM, Mandal RV, Kay J. Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. Arch Pathol Lab Med. 2009 Dec; 133(12):1943-8.
    View in: PubMed
    Score: 0.013
  44. Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology. 2009 Oct; 253(1):81-9.
    View in: PubMed
    Score: 0.013
  45. Kay J, Westhovens R. Methotrexate: the gold standard without standardisation. Ann Rheum Dis. 2009 Jul; 68(7):1081-2.
    View in: PubMed
    Score: 0.013
  46. Collier DS, Grant RW, Estey G, Surrao D, Chueh HC, Kay J. Physician ability to assess rheumatoid arthritis disease activity using an electronic medical record-based disease activity calculator. Arthritis Rheum. 2009 Apr 15; 61(4):495-500.
    View in: PubMed
    Score: 0.012
  47. Kay J. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis. 2008 Dec; 67 Suppl 3:iii66-9.
    View in: PubMed
    Score: 0.012
  48. Kay J. Nephrogenic systemic fibrosis: a new concern for rheumatologists. Nat Clin Pract Rheumatol. 2008 Sep; 4(9):445.
    View in: PubMed
    Score: 0.012
  49. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008 Aug; 58(8):2543-8.
    View in: PubMed
    Score: 0.012
  50. Todd DJ, Kay J. Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Curr Rheumatol Rep. 2008 Jul; 10(3):195-204.
    View in: PubMed
    Score: 0.012
  51. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z, Visvanathan S, Rahman MU. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008 Apr; 58(4):964-75.
    View in: PubMed
    Score: 0.012
  52. Kay J, Bazari H, Avery LL, Koreishi AF. Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med. 2008 Feb 21; 358(8):827-38.
    View in: PubMed
    Score: 0.012
  53. Kay J. Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med. 2008 Feb; 75(2):112, 114, 117.
    View in: PubMed
    Score: 0.011
  54. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007 Oct; 56(10):3433-41.
    View in: PubMed
    Score: 0.011
  55. Kay J, Finn DS, Stone JR. Case records of the Massachusetts General Hospital. Case 4-2006. A 79-year-old woman with myalgias, fatigue, and shortness of breath. N Engl J Med. 2006 Feb 09; 354(6):623-30.
    View in: PubMed
    Score: 0.010
  56. Kay J, McCluskey RT. Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency. N Engl J Med. 2005 Oct 13; 353(15):1605-13.
    View in: PubMed
    Score: 0.010
  57. Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2004 Jun; 43 Suppl 3:iii2-iii9.
    View in: PubMed
    Score: 0.009
  58. Shridharmurthy D, Lapane KL, Baek J, Nunes AP, Weisman MH, Kay J, Liu SH. Sex Differences in Time to Initiate Nonsteroidal Anti-Inflammatory Drugs or Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2024 08; 76(8):1149-1161.
    View in: PubMed
    Score: 0.009
  59. Choufani M, Kay J, Ermann J. Axial spondyloarthritis guidelines - aiming for maximum impact. Curr Opin Rheumatol. 2024 07 01; 36(4):251-260.
    View in: PubMed
    Score: 0.009
  60. Navarro-Comp?n V, Ramiro S, Deodhar A, Mease PJ, Rudwaleit M, de la Loge C, Fleurinck C, Taieb V, M?rup MF, Massow U, Kay J, Magrey M. Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD Open. 2024 04 10; 10(2).
    View in: PubMed
    Score: 0.009
  61. Winthrop KL, Mease P, Kerschbaumer A, Voll RE, Breedveld FC, Smolen JS, Gottenberg JE, Baraliakos X, Kiener HP, Aletaha D, Isaacs JD, Buch MH, Crow MK, Kay J, Crofford L, van Vollenhoven RF, Ospelt C, Siebert S, Kloppenburg M, McInnes IB, Huizinga TW, Gravallese EM. Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023. Ann Rheum Dis. 2024 Mar 12; 83(4):409-416.
    View in: PubMed
    Score: 0.009
  62. Shridharmurthy D, Lapane KL, Nunes AP, Baek J, Weisman MH, Kay J, Liu SH. Postpartum Depression in Reproductive-Age Women With and Without Rheumatic Disease: A Population-Based Matched Cohort Study. J Rheumatol. 2023 10; 50(10):1287-1295.
    View in: PubMed
    Score: 0.008
  63. Saudek DM, Kay J. Advanced glycation endproducts and osteoarthritis. Curr Rheumatol Rep. 2003 Feb; 5(1):33-40.
    View in: PubMed
    Score: 0.008
  64. Shridharmurthy D, Lapane KL, Baek J, Nunes A, Kay J, Liu SH. Comanagement with rheumatology and prescription biologics filled during pregnancy in women with rheumatic diseases: a retrospective analysis of US administrative claims data. BMJ Open. 2022 12 22; 12(12):e065189.
    View in: PubMed
    Score: 0.008
  65. Rahrmann EP, Shorthouse D, Jassim A, Hu LP, Ortiz M, Mahler-Araujo B, Vogel P, Paez-Ribes M, Fatemi A, Hannon GJ, Iyer R, Blundon JA, Louren?o FC, Kay J, Nazarian RM, Hall BA, Zakharenko SS, Winton DJ, Zhu L, Gilbertson RJ. The NALCN channel regulates metastasis and nonmalignant cell dissemination. Nat Genet. 2022 12; 54(12):1827-1838.
    View in: PubMed
    Score: 0.008
  66. Menter A, Cohen S, Kay J, Strand V, Gottlieb A, Hanauer S, Eduru SK, Buschke S, Lang B, Liesenfeld KH, Schaible J, McCabe D. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. 2022 Sep; 23(5):719-728.
    View in: PubMed
    Score: 0.008
  67. Shridharmurthy D, Lapane KL, Khan S, Yi E, Baek J, Kay J, Liu SH. Development and test-retest reliability of a screening tool for axial spondyloarthritis. PLoS One. 2022; 17(7):e0269494.
    View in: PubMed
    Score: 0.008
  68. Furst DE, Jaworski J, Wojciechowski R, Wiland P, Dudek A, Krogulec M, Jeka S, Zielinska A, Trefler J, Bartnicka-Maslowska K, Krajewska-Wlodarczyk M, Klimiuk PA, Lee SJ, Kim SH, Bae YJ, Yang GE, Yoo JK, Kay J, Keystone E. Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. Rheumatology (Oxford). 2022 04 11; 61(4):1385-1395.
    View in: PubMed
    Score: 0.008
  69. Casato M, Mecucci C, Agnello V, Fiorilli M, Knight GB, Matteucci C, Gao L, Kay J. Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood. 2002 Mar 15; 99(6):2259-61.
    View in: PubMed
    Score: 0.008
  70. Shridharmurthy D, Khan S, Lapane KL, Yi E, Kay J, Liu SH. Development of a screening tool to identify patients with axial spondyloarthritis: a cognitive interview study. Clin Rheumatol. 2022 May; 41(5):1391-1402.
    View in: PubMed
    Score: 0.008
  71. Khan S, Shridharmurthy D, Lapane KL, Dube C, Kay J, Yi E, Liu SH. The disease burden of axial spondyloarthritis: through a gendered lens. Clin Rheumatol. 2022 Apr; 41(4):1115-1124.
    View in: PubMed
    Score: 0.008
  72. Lapane KL, Dub? C, Ferrucci K, Khan S, Kuhn KA, Yi E, Kay J, Liu SH. Patient perspectives on health care provider practices leading to an axial spondyloarthritis diagnosis: an exploratory qualitative research study. BMC Fam Pract. 2021 12 20; 22(1):251.
    View in: PubMed
    Score: 0.008
  73. Lapane KL, Shridharmurthy D, Khan S, Lindstrom D, Beccia A, Yi E, Kay J, Dube C, Liu SH. Primary care physician perspectives on screening for axial spondyloarthritis: A qualitative study. PLoS One. 2021; 16(5):e0252018.
    View in: PubMed
    Score: 0.007
  74. Davidson A, Brimhall D, Kay J, Keystone E, Lee SJ, Kim SH, Bae YJ, Choi EJ, Furst DE. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40?mg/0.4?mL) by autoinjector and prefilled syringe in healthy subjects. Br J Clin Pharmacol. 2021 11; 87(11):4323-4333.
    View in: PubMed
    Score: 0.007
  75. Shridharmurthy D, Zhao D, Lapane KL, Baek J, Kay J, Liu SH. Disease Burden and Health-Related Quality of Life Among Women and Men with Spondyloarthritis: An Exploratory Analysis of a Population-Based Sample. J Womens Health (Larchmt). 2021 11; 30(11):1637-1644.
    View in: PubMed
    Score: 0.007
  76. Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, Chopra A, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy JS, Jahreis A, Mozaffarian N, Messina OD, Landew? RB, Atsumi T, Burmester GR. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021 06; 80(6):727-738.
    View in: PubMed
    Score: 0.007
  77. Lapane KL, Khan S, Shridharmurthy D, Beccia A, Dub? C, Yi E, Kay J, Liu SH. Primary care physician perspectives on barriers to diagnosing axial Spondyloarthritis: a qualitative study. BMC Fam Pract. 2020 09 29; 21(1):204.
    View in: PubMed
    Score: 0.007
  78. Kay J, Bardin T. Osteoarticular disorders of renal origin: disease-related and iatrogenic. Baillieres Best Pract Res Clin Rheumatol. 2000 Jun; 14(2):285-305.
    View in: PubMed
    Score: 0.007
  79. Curtis JR, Xie F, Kay J, Kallich JD. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. Arthritis Res Ther. 2019 12 12; 21(1):285.
    View in: PubMed
    Score: 0.007
  80. Kay JH, Altshuler LL, Ventura J, Mintz J. Prevalence of axis II comorbidity in bipolar patients with and without alcohol use disorders. Ann Clin Psychiatry. 1999 Dec; 11(4):187-95.
    View in: PubMed
    Score: 0.007
  81. Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landew? R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D. A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019 07; 71(7):1101-1111.
    View in: PubMed
    Score: 0.006
  82. Kay J. Beta 2-microglobulin amyloidosis in renal failure: understanding this recently recognized condition. Cleve Clin J Med. 1999 Mar; 66(3):145-7.
    View in: PubMed
    Score: 0.006
  83. Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Ann Rheum Dis. 2019 07; 78(7):872-878.
    View in: PubMed
    Score: 0.006
  84. Dzubur E, Khalil C, Almario CV, Noah B, Minhas D, Ishimori M, Arnold C, Park Y, Kay J, Weisman MH, Spiegel BMR. Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media Platforms. Arthritis Care Res (Hoboken). 2019 02; 71(2):323-330.
    View in: PubMed
    Score: 0.006
  85. Bridges SL, White DW, Worthing AB, Gravallese EM, O'Dell JR, Nola K, Kay J, Cohen SB. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. Arthritis Rheumatol. 2018 03; 70(3):334-344.
    View in: PubMed
    Score: 0.006
  86. Gravallese EM, Kay J, Duryea J, Solomon DH. Reply. Arthritis Rheumatol. 2018 03; 70(3):476.
    View in: PubMed
    Score: 0.006
  87. Baecklund E, Backlin C, R?nnelid J, Toes R, Huizinga T, ?hlin E, Askling J, Hochberg FH, Klareskog L, Kay J, Smedby KE. Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. Scand J Rheumatol. 2018 07; 47(4):270-275.
    View in: PubMed
    Score: 0.006
  88. Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE. The unmet need in rheumatology: Reports from the targeted therapies meeting 2017. Clin Immunol. 2018 01; 186:87-93.
    View in: PubMed
    Score: 0.006
  89. Solomon DH, Kay J, Duryea J, Lu B, Bolster MB, Yood RA, Han R, Ball S, Coleman C, Lo E, Wohlfahrt A, Sury M, Yin M, Yu Z, Zak A, Gravallese EM. Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2017 09; 69(9):1741-1750.
    View in: PubMed
    Score: 0.006
  90. Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Blanco R, Kadva A, Dimonaco S. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017 Jul; 76(7):1279-1284.
    View in: PubMed
    Score: 0.005
  91. Stavre Z, Upchurch K, Kay J, Gravallese EM. Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis. Curr Rheumatol Rep. 2016 Dec; 18(12):72.
    View in: PubMed
    Score: 0.005
  92. Goyal A, Linskey KR, Kay J, Duncan LM, Nazarian RM. Differential Expression of Hedgehog and Snail in Cutaneous Fibrosing Disorders: Implications for Targeted Inhibition. Am J Clin Pathol. 2016 Dec; 146(6):709-717.
    View in: PubMed
    Score: 0.005
  93. Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, Engel B, Flader C, Kay J, Matsuoka M, Perez-Ruiz F, da Rocha Castelar-Pinheiro G, Saag K, So A, Vazquez Mellado J, Weisman M, Westhoff TH, Yamanaka H, Braun J. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017 04; 76(4):632-638.
    View in: PubMed
    Score: 0.005
  94. Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE. The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016. Clin Exp Rheumatol. 2016 Jul-Aug; 34(4 Suppl 98):69-76.
    View in: PubMed
    Score: 0.005
  95. Chertow GM, Trimbur T, Karlson EW, Lazarus JM, Kay J. Performance characteristics of a dialysis-related amyloidosis questionnaire. J Am Soc Nephrol. 1996 Aug; 7(8):1235-40.
    View in: PubMed
    Score: 0.005
  96. D?rner T, Strand V, Cornes P, Gon?alves J, Gul?csi L, Kay J, Kvien TK, Smolen J, Tanaka Y, Burmester GR. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016 06; 75(6):974-82.
    View in: PubMed
    Score: 0.005
  97. Duryea J, Russell R, Gravallese EM, Kay J, Han R, Lu B, Solomon DH. Brief Report: Development and Validation of a Semiautomated Method to Measure Erosion Volume in Inflammatory Arthritis by Computed Tomography Scanning. Arthritis Rheumatol. 2016 Feb; 68(2):332-6.
    View in: PubMed
    Score: 0.005
  98. Deodhar A, Strand V, Kay J, Braun J. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016 May; 75(5):791-4.
    View in: PubMed
    Score: 0.005
  99. Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016 Jun; 75(6):1081-91.
    View in: PubMed
    Score: 0.005
  100. Gvozdenovic E, Wolterbeek R, Allaart CF, Brenol C, Dougados M, Emery P, Ferraccioli G, van der Heijde D, Huizinga TW, Kay J, Martin Mola E, Moots RJ, da Silva JA, Smolen J, Veale D, Landew? RB. Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database. J Clin Rheumatol. 2015 Oct; 21(7):349-54.
    View in: PubMed
    Score: 0.005
  101. Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. Int J Rheum Dis. 2016 Nov; 19(11):1143-1156.
    View in: PubMed
    Score: 0.005
  102. Navarro-Comp?n V, Smolen JS, Huizinga TW, Landew? R, Ferraccioli G, da Silva JA, Moots RJ, Kay J, van der Heijde D. Quality indicators in rheumatoid arthritis: results from the METEOR database. Rheumatology (Oxford). 2015 Sep; 54(9):1630-9.
    View in: PubMed
    Score: 0.005
  103. Smolen JS, Kay J, Doyle M, Landew? R, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Xu S, Zhou Y, Hsia EC. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor a inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther. 2015 Jan 22; 17:14.
    View in: PubMed
    Score: 0.005
  104. Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014 Jul; 69(7):661-8.
    View in: PubMed
    Score: 0.004
  105. Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao L, Fiore S, Momtahen T, Yancopoulos GD, Stahl N, Inman RD. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015 Jun; 74(6):1051-7.
    View in: PubMed
    Score: 0.004
  106. Kay J, Czop JK. Enhancement of human monocyte beta-glucan receptors by glucocorticoids. Immunology. 1994 Jan; 81(1):96-102.
    View in: PubMed
    Score: 0.004
  107. Smolen JS, Kay J, Matteson EL, Landew? R, Hsia EC, Xu S, Zhou Y, Doyle MK. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis. 2014 Oct; 73(10):1811-8.
    View in: PubMed
    Score: 0.004
  108. Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013 Oct; 52(10):1845-55.
    View in: PubMed
    Score: 0.004
  109. Le LP, Garibyan L, Lara D, Finberg KE, Iafrate AJ, Duncan LM, Kay J, Nazarian RM. Fibrosis-associated single-nucleotide polymorphisms in TGFB1 and CAV1 are not associated with the development of nephrogenic systemic fibrosis. Am J Dermatopathol. 2013 May; 35(3):351-6.
    View in: PubMed
    Score: 0.004
  110. Vital EM, Kay J, Emery P. Rituximab biosimilars. Expert Opin Biol Ther. 2013 Jul; 13(7):1049-62.
    View in: PubMed
    Score: 0.004
  111. Kay J, Preibisz JM. Lyme disease. Compr Ther. 1993; 19(4):157-62.
    View in: PubMed
    Score: 0.004
  112. Schneeberger D, Tyndall A, Kay J, S?ndergaard KH, Carreira PE, Morgiel E, Deuschle K, Derk CT, Widuchowska M, Walker UA. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology (Oxford). 2013 Mar; 52(3):560-7.
    View in: PubMed
    Score: 0.004
  113. Kay J, Benson CB, Lester S, Corson JM, Pinkus GS, Lazarus JM, Owen WF. Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum. 1992 Aug; 35(8):926-32.
    View in: PubMed
    Score: 0.004
  114. Smolen JS, Kay J, Landew? RB, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Zhou Y, Hsia EC, Doyle MK. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis. 2012 Oct; 71(10):1671-9.
    View in: PubMed
    Score: 0.004
  115. Lin HW, Roberts DS, Kay J, Stankovic KM. Sensorineural hearing loss following imatinib (Gleevec) administration. Otolaryngol Head Neck Surg. 2012 Feb; 146(2):335-7.
    View in: PubMed
    Score: 0.004
  116. Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol. 2011 Dec; 65(6):1095-1106.e7.
    View in: PubMed
    Score: 0.004
  117. Kay J, Austen KF, Czop JK. Identification and characterization of opsonic fibronectin in synovial fluids of patients with active rheumatoid arthritis. Arthritis Rheum. 1991 Jun; 34(6):687-96.
    View in: PubMed
    Score: 0.004
  118. Czop JK, Kay J. Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes. J Exp Med. 1991 Jun 01; 173(6):1511-20.
    View in: PubMed
    Score: 0.004
  119. Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology. 2011 Jul; 260(1):105-11.
    View in: PubMed
    Score: 0.004
  120. Nazarian RM, Mandal RV, Kagan A, Kay J, Duncan LM. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid. J Am Acad Dermatol. 2011 Apr; 64(4):741-7.
    View in: PubMed
    Score: 0.004
  121. Wasko MC, Kay J, Hsia EC, Rahman MU. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken). 2011 Apr; 63(4):512-21.
    View in: PubMed
    Score: 0.004
  122. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, M?nard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep; 69(9):1580-8.
    View in: PubMed
    Score: 0.003
  123. Funovits J, Aletaha D, Bykerk V, Combe B, Dougados M, Emery P, Felson D, Hawker G, Hazes JM, Huizinga T, Kay J, Kvien TK, Smolen JS, Symmons D, Tak PP, Silman A. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis. 2010 Sep; 69(9):1589-95.
    View in: PubMed
    Score: 0.003
  124. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, M?nard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsk? J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep; 62(9):2569-81.
    View in: PubMed
    Score: 0.003
  125. Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal R, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Khanna D, Kvien TK, Laing T, Liao K, Mease P, M?nard HA, Moreland LW, Nair R, Pincus T, Ringold S, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsk? J, Wolfe F, Hawker G. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010 Sep; 62(9):2582-91.
    View in: PubMed
    Score: 0.003
  126. Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am. 2010 May; 36(2):385-404.
    View in: PubMed
    Score: 0.003
  127. Kroshinsky D, Kay J, Nazarian RM. Case records of the Massachusetts General Hospital. Case 37-2009. A 46-year-old woman with chronic renal failure, leg swelling, and skin changes. N Engl J Med. 2009 Nov 26; 361(22):2166-76.
    View in: PubMed
    Score: 0.003
  128. Smolen JS, Kay J, Doyle MK, Landew? R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009 Jul 18; 374(9685):210-21.
    View in: PubMed
    Score: 0.003
  129. Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. J Rheumatol. 2009 Jul; 36(7):1371-9.
    View in: PubMed
    Score: 0.003
  130. Collier DS, Kay J, Estey G, Surrao D, Chueh HC, Grant RW. A rheumatology-specific informatics-based application with a disease activity calculator. Arthritis Rheum. 2009 Apr 15; 61(4):488-94.
    View in: PubMed
    Score: 0.003
  131. Kay J, Eichenfield AH, Athreya BH, Doughty RA, Schumacher HR. Synovial fluid eosinophilia in Lyme disease. Arthritis Rheum. 1988 Nov; 31(11):1384-9.
    View in: PubMed
    Score: 0.003
  132. Sarraf P, Kay J, Reginato AM. Non-crystalline and crystalline rheumatic disorders in chronic kidney disease. Curr Rheumatol Rep. 2008 Jul; 10(3):235-48.
    View in: PubMed
    Score: 0.003
  133. Cha JH, Furie K, Kay J, Walensky RP, Mullins ME, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 39-2006. A 24-year-old woman with systemic lupus erythematosus, seizures, and right arm weakness. N Engl J Med. 2006 Dec 21; 355(25):2678-89.
    View in: PubMed
    Score: 0.003
  134. Sarraf P, Kay J, Friday RP, Reginato AM. Wegener's granulomatosis: is biologic therapy useful? Curr Rheumatol Rep. 2006 Aug; 8(4):303-11.
    View in: PubMed
    Score: 0.003
  135. Moschella SL, Kay J, Mackool BT, Liu V. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med. 2004 Nov 18; 351(21):2219-27.
    View in: PubMed
    Score: 0.002
  136. Kay J, Stricker RB. Hematologic and immunologic abnormalities in anorexia nervosa. South Med J. 1983 Aug; 76(8):1008-10.
    View in: PubMed
    Score: 0.002
  137. Hou FF, Miyata T, Boyce J, Yuan Q, Chertow GM, Kay J, Schmidt AM, Owen WF. beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney Int. 2001 Mar; 59(3):990-1002.
    View in: PubMed
    Score: 0.002
  138. Jimenez RE, Price DA, Pinkus GS, Owen WF, Lazarus JM, Kay J, Turner JR. Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis. Am J Surg Pathol. 1998 Jun; 22(6):729-35.
    View in: PubMed
    Score: 0.001
  139. Owen WF, Hou FF, Stuart RO, Kay J, Boyce J, Chertow GM, Schmidt AM. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int. 1998 May; 53(5):1365-73.
    View in: PubMed
    Score: 0.001
  140. Hou FF, Boyce J, Chertow GM, Kay J, Owen WF. Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin. J Am Soc Nephrol. 1998 Feb; 9(2):277-83.
    View in: PubMed
    Score: 0.001
  141. Hou FF, Chertow GM, Kay J, Boyce J, Lazarus JM, Braatz JA, Owen WF. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Kidney Int. 1997 May; 51(5):1514-9.
    View in: PubMed
    Score: 0.001
  142. Gravallese EM, Baker N, Lester S, Kay J, Owen WF. Musculoskeletal manifestations in beta 2-microglobulin amyloidosis. Case discussion. Arthritis Rheum. 1992 May; 35(5):592-602.
    View in: PubMed
    Score: 0.001
  143. Matsuyama T, Yamada A, Kay J, Yamada KM, Akiyama SK, Schlossman SF, Morimoto C. Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex. J Exp Med. 1989 Oct 01; 170(4):1133-48.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.